Morbidity and mortality in systemic lupus erythematosus

Harefuah

Volumn 140, Issue 12, 2001, Pages 1159-1162+1229

  Marai, Ibrahim ^a   Levi, Yair ^a   Shoenfeld, Yehuda ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; DEATH; DISEASE COURSE; HUMAN; MORBIDITY; MORTALITY; PERIPHERAL NERVOUS SYSTEM; RESPIRATORY ARREST; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0035695628     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy
2. Subacute and chronic active hepatitis after withdrawal of chemotherapy
3. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
4. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosupressive therapy in hepatitis B carriers
5. Reactivation of Hepatitis B virus replication in patient receiving cytotoxic therapy. Report of a prospective study
6. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991
7. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of theproblem
8. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risks factors
9. Hepatitis B virus DNA contains a glucocorticoid responsive element
10. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment
11. Effect of Alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
12. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis
13. Antiviral chemotherapy for the treatment of hepatitis B virus infections
14. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation
15. A one year trial of lamivudine for chronic hepatitis B
16. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infections
17. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
18. Efficacy of lamivudine in patient with hepatitis B e antigen negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
19. Successful treatment with Lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma
20. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
21. Lamivudine allows completion of chemotherapy in Lymphoma patients with hepatitis B reactivation
22. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management
23. Ablation of persistent hepatitis B by BMT from a hepatitis B immune donor